Akari Therapeutics PLC Form 4 insider transactions

Kameel D. Farag, Interim CFO of Akari Therapeutics Plc, received 1,130 shares of common stock on July 16, 2026.

Samir Rashmikant Patel, a Director and 10% owner of Akari Therapeutics Plc, reported multiple transactions in common stock on July 7, 2026.

Kameel D. Farag, Interim CFO of Akari Therapeutics Plc, reported transactions involving the acquisition of American Depositary Shares.

Akari Therapeutics Plc reports a Form 4 filing detailing stock option transactions by CEO Abizer Gaslightwala.

Akari Therapeutics Director James R. Neal acquired various warrants to purchase American Depositary Shares through a private placement and a debt-for-equity exchange.

Akari Therapeutics Director Raymond Prudo-Chlebosz acquired over 2 million derivative securities, including warrants and pre-funded warrants, through a private placement and a note exchange agreement.

Akari Therapeutics director Sandip Patel acquired warrants and pre-funded warrants, including some through a private placement and others by converting an outstanding promissory note.

Akari Therapeutics director and 10% owner Hoyoung Huh increased beneficial ownership through a private placement of warrants and an exchange of a promissory note for additional warrants.

Akari Therapeutics' Interim CFO, Kameel D. Farag, acquired pre-funded warrants and Series G warrants to purchase American Depositary Shares in a private placement transaction.

Akari Therapeutics director and 10% owner Samir Patel acquired significant warrants and pre-funded warrants in a private placement and a note exchange agreement.

Akari Therapeutics CEO and Director Abizer Gaslightwala acquired significant warrants and pre-funded warrants through a private placement and a note exchange, pending shareholder approval.

Akari Therapeutics Director Robert Bazemore acquired significant warrants and pre-funded warrants through a private placement and a debt-to-equity exchange, pending shareholder approval.

Akari Therapeutics' Interim CFO, Kameel D. Farag, was granted restricted stock units representing 58,619 American Depositary Shares.

Akari Therapeutics' Interim CFO, Kameel D. Farag, acquired 6,277 American Depositary Shares representing restricted stock units.

Akari Therapeutics CEO Abizer Gaslightwala acquired 21,000 American Depositary Shares for approximately $19,540 through open market purchases in late August 2025.

Akari Therapeutics Plc's President and CEO, Abizer Gaslightwala, has increased his direct beneficial ownership in the company through recent purchases of American Depositary Shares (ADSs).

Akari Therapeutics Plc's President and CEO, Abizer Gaslightwala, has acquired 10,000 American Depositary Shares, signaling increased insider confidence in the company.

Abizer Gaslightwala, President & CEO and Director of Akari Therapeutics Plc, has acquired 15,000 American Depositary Shares (ADS) in the company, signaling strong insider confidence.

Akari Therapeutics Plc's CEO and Director, Abizer Gaslightwala, acquired a total of 45,000 American Depositary Shares (ADS) in open market transactions on June 12 and June 13, 2025.

Akari Therapeutics Plc's CEO and Director, Abizer Gaslightwala, acquired 20,000 American Depositary Shares (ADS) for $25,400, increasing his beneficial ownership to 201,428 ADS.

Director Sandip I. Patel acquired shares and warrants of Akari Therapeutics Plc through a private placement, as disclosed in a Form 4 filing with the SEC.

Director James R. Neal of Akari Therapeutics Plc reports acquisition of stock options and ownership of American Depositary Shares.

Director Robert B. Bazemore reports acquisition of stock options and American Depositary Shares in Akari Therapeutics Plc.

Director Samir Rashmikant Patel reports acquisition of stock options in Akari Therapeutics Plc.

Director Sandip I. Patel reports the acquisition of stock options and updates to beneficial ownership of Akari Therapeutics Plc shares.

Director Raymond Prudo-Chlebosz reports acquisition of stock options and beneficial ownership of Akari Therapeutics shares.

CFO of Akari Therapeutics, Torsten Hombeck, reports the acquisition of stock options and American Depositary Shares (ADS) representing Ordinary Shares.

Director Hoyoung Huh reports acquisition of Akari Therapeutics shares and stock options, indicating changes in beneficial ownership.

Director Abizer Gaslightwala receives stock options in Akari Therapeutics Plc, including performance-based options tied to financing or licensing milestones.

Director Hoyoung Huh acquired shares and warrants in Akari Therapeutics through a private placement, signaling a potential increase in stake.